- Home
- ATIP vs CVKD Comparison
ATIP vs CVKD Comparison
Compare ATIP & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIP
- CVKD
- Stock Information
- Founded
- ATIP 1996
- CVKD 2022
- Country
- ATIP United States
- CVKD United States
- Employees
- ATIP N/A
- CVKD N/A
- Industry
- ATIP Hospital/Nursing Management
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- ATIP Health Care
- CVKD Health Care
- Exchange
- ATIP Nasdaq
- CVKD Nasdaq
- Market Cap
- ATIP 26.0M
- CVKD 26.3M
- IPO Year
- ATIP N/A
- CVKD 2023
- Fundamental
- Price
- ATIP $1.96
- CVKD $15.66
- Analyst Decision
- ATIP
- CVKD Strong Buy
- Analyst Count
- ATIP 0
- CVKD 2
- Target Price
- ATIP N/A
- CVKD $46.00
- AVG Volume (30 Days)
- ATIP 53.9K
- CVKD 81.0K
- Earning Date
- ATIP 11-04-2024
- CVKD 11-07-2024
- Dividend Yield
- ATIP N/A
- CVKD N/A
- EPS Growth
- ATIP N/A
- CVKD N/A
- EPS
- ATIP N/A
- CVKD N/A
- Revenue
- ATIP $728,114,000.00
- CVKD N/A
- Revenue This Year
- ATIP $10.52
- CVKD N/A
- Revenue Next Year
- ATIP $4.57
- CVKD N/A
- P/E Ratio
- ATIP N/A
- CVKD N/A
- Revenue Growth
- ATIP 9.29
- CVKD N/A
- 52 Week Low
- ATIP $1.92
- CVKD $5.40
- 52 Week High
- ATIP $7.93
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- ATIP 9.93
- CVKD 50.92
- Support Level
- ATIP $2.52
- CVKD $16.25
- Resistance Level
- ATIP $3.32
- CVKD $19.97
- Average True Range (ATR)
- ATIP 0.61
- CVKD 1.91
- MACD
- ATIP -0.26
- CVKD -0.18
- Stochastic Oscillator
- ATIP 0.98
- CVKD 27.81
About ATIP ATI Physical Therapy Inc.
ATI Physical Therapy Inc is a recognized outpatient physical therapy provider in the United States specializing in outpatient rehabilitation and adjacent healthcare services. It offer a variety of services within the clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.